413 related articles for article (PubMed ID: 22510338)
21. Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca-Charles River Laboratories strategic relationship.
Martin FDC; Benjamin A; MacLean R; Hollinshead DM; Landqvist C
Drug Discov Today; 2017 Dec; 22(12):1754-1759. PubMed ID: 28851537
[TBL] [Abstract][Full Text] [Related]
22. Outsourcing lead optimisation--the quiet revolution.
Clark DE; Newton CG
Drug Discov Today; 2004 Jun; 9(11):492-500. PubMed ID: 15149625
[TBL] [Abstract][Full Text] [Related]
23. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals.
Claude JR; Claude N
Toxicol Lett; 2004 Jun; 151(1):25-8. PubMed ID: 15177637
[TBL] [Abstract][Full Text] [Related]
24. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.
Valentin JP; Bass AS; Atrakchi A; Olejniczak K; Kannosuke F
J Pharmacol Toxicol Methods; 2005; 52(1):22-9. PubMed ID: 15961324
[TBL] [Abstract][Full Text] [Related]
25. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
[TBL] [Abstract][Full Text] [Related]
26. The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment.
Abi-Gerges N; McMahon C; Vargas H; Sager P; Chui R; Stevens D; Davila J; Schaub JR; Wu JC; Del Rio C; Mathes C; Miller PE; Burns-Naas LA; Ghetti A
J Pharmacol Toxicol Methods; 2019; 98():106582. PubMed ID: 31077805
[TBL] [Abstract][Full Text] [Related]
27. Current practice and perspectives in CRO oversight based on a survey performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
Hennig M; Hundt F; Busta S; Mikus S; Sanden PH; Sörgel A; Ruppert T
Ger Med Sci; 2017; 15():Doc02. PubMed ID: 28163667
[TBL] [Abstract][Full Text] [Related]
28. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
29. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
[TBL] [Abstract][Full Text] [Related]
30. An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation.
Authier S; Abernathy MM; Correll K; Chui RW; Dalton J; Foley CM; Friedrichs GS; Koerner JE; Kallman MJ; Pannirselvam M; Redfern WS; Urmaliya V; Valentin JP; Wisialowski T; Zabka TS; Pugsley MK
Int J Toxicol; 2020; 39(4):274-293. PubMed ID: 32406289
[TBL] [Abstract][Full Text] [Related]
31. Safety pharmacology investigations on the nervous system: An industry survey.
Authier S; Arezzo J; Delatte MS; Kallman MJ; Markgraf C; Paquette D; Pugsley MK; Ratcliffe S; Redfern WS; Stevens J; Valentin JP; Vargas HM; Curtis MJ
J Pharmacol Toxicol Methods; 2016; 81():37-46. PubMed ID: 27263834
[TBL] [Abstract][Full Text] [Related]
32. Outsourcing lead optimization: the eye of the storm.
Clark DE
Drug Discov Today; 2011 Feb; 16(3-4):147-57. PubMed ID: 21145413
[TBL] [Abstract][Full Text] [Related]
33. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
[TBL] [Abstract][Full Text] [Related]
34. An overview of some pharmacological methods used in safety pharmacology studies.
Pugsley MK
Proc West Pharmacol Soc; 2004; 47():18-22. PubMed ID: 15633602
[TBL] [Abstract][Full Text] [Related]
35. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
36. Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.
Bass AS; Vargas HM; Valentin JP; Kinter LB; Hammond T; Wallis R; Siegl PK; Yamamoto K
J Pharmacol Toxicol Methods; 2011; 64(1):7-15. PubMed ID: 21689769
[TBL] [Abstract][Full Text] [Related]
37. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.
Ewart L; Milne A; Adkins D; Benjamin A; Bialecki R; Chen Y; Ericsson AC; Gardner S; Grant C; Lengel D; Lindgren S; Lowing S; Marks L; Moors J; Oldman K; Pietras M; Prior H; Punton J; Redfern WS; Salmond R; Skinner M; Some M; Stanton A; Swedberg M; Finch J; Valentin JP
J Pharmacol Toxicol Methods; 2013; 68(1):30-43. PubMed ID: 23665080
[TBL] [Abstract][Full Text] [Related]
38. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
39. The shifting landscape of safety pharmacology in 2015.
Pugsley MK; Authier S; Stonerook M; Curtis MJ
J Pharmacol Toxicol Methods; 2015; 75():5-9. PubMed ID: 26055120
[TBL] [Abstract][Full Text] [Related]
40. Response of safety pharmacologists to challenges arising from the rapidly evolving changes in the pharmaceutical industry.
Bass AS; Pugsley MK; Sannajust F; Yoshinaga T; Valentin JP
J Pharmacol Toxicol Methods; 2019; 98():106593. PubMed ID: 31158459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
